| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Multi-institutional phase I trials of anticancer agents. | J Clin Oncol | 2008 | 1.65 |
| 2 | Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. | Lung Cancer | 2006 | 1.06 |
| 3 | Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. | Invest New Drugs | 2005 | 0.77 |
| 4 | Temporal evolution of patient characteristics enrolled on phase I trials. | Invest New Drugs | 2009 | 0.75 |